Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Wyeth/Amgen's Enbrel (etanercept) will achieve blockbuster status for the treatment of psoriasis by 2010. Because physicians recognize Enbrel as the biologic therapy that provides the best balance of safety and efficacy, it will continue to lead sales among biologics approved for psoriasis through 2015, despite competition from Abbott/Eisai's Humira (adalimumab) after its expected launch.
The new Pharmacor report entitled Psoriasis finds that despite slow growth in psoriasis prevalence, modest diagnosis rates, and a small drug-treated population, the market to treat the disease will more than double from $1.5 billion in 2005 to over $3.5 billion by 2015 in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The increasing demand for biologics and the introduction of new agents for moderate-to-severe psoriasis will drive this growth. The report also finds that, although dermatologists increasingly endorse the use of biologics for psoriasis, the extent to which biologics will penetrate the market will depend on third-party payers.
"The most important constraint on the uptake of biologics in the psoriasis market will come from third-party payers as they scrutinize each biologic agent's cost-effectiveness," said Joanna Kim, analyst at Decision Resources, Inc. "At present, the reimbursement environment for psoriasis in the United States is more permissive than in Europe. However, this scenario will likely change as payers universally tighten their control over the use of biologics and weigh the relatively low disease burden of psoriasis against the more urgent medical needs that biologics address for conditions such as rheumatoid arthritis."
Psoriasis is a lifelong inflammatory skin condition that affects 1 to 2% of the populations under study. Psoriasis is thought to arise from a combination of factors, including genetics, environmental triggers, associated diseases (particularly infection), and immunological status.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/